Discovery of thiosemicarbazone derivatives as effective New Delhi metallo-ß-lactamase-1 (NDM-1) inhibitors against NDM-1 producing clinical isolates.
Acta Pharm Sin B
; 11(1): 203-221, 2021 Jan.
Article
en En
| MEDLINE
| ID: mdl-33532189
New Delhi metallo-ß-lactamase-1 (NDM-1) is capable of hydrolyzing nearly all ß-lactam antibiotics, posing an emerging threat to public health. There are currently less effective treatment options for treating NDM-1 positive "superbug", and no promising NDM-1 inhibitors were used in clinical practice. In this study, structure-activity relationship based on thiosemicarbazone derivatives was systematically characterized and their potential activities combined with meropenem (MEM) were evaluated. Compounds 19bg and 19bh exhibited excellent activity against 10 NDM-positive isolate clinical isolates in reversing MEM resistance. Further studies demonstrated compounds 19bg and 19bh were uncompetitive NDM-1 inhibitors with Ki = 0.63 and 0.44 µmol/L, respectively. Molecular docking speculated that compounds 19bg and 19bh were most likely to bind in the allosteric pocket which would affect the catalytic effect of NDM-1 on the substrate meropenem. Toxicity evaluation experiment showed that no hemolysis activities even at concentrations of 1000 mg/mL against red blood cells. In vivo experimental results showed combination of MEM and compound 19bh was markedly effective in treating infections caused by NDM-1 positive strain and prolonging the survival time of sepsis mice. Our finding showed that compound 19bh might be a promising lead in developing new inhibitor to treat NDM-1 producing superbug.
(Boc)2O, di-tert-butyl decarbonate; 3-AP, 3-aminopyridine carboxaldehyde thiosemicarbazone; AcOH, acetic acid; Antibiotic resistance; Boc, tert-butoxycarbonyl; CLSI, Clinical and Laboratory Standards Institute; DMAP, 4-dimethylaminopyridine; DpC, di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone; E. coli, Escherichia coli; EDTA, ethylene diamine tetraacetic acid; ESI, electrospray ionization; HR-MS, high-resolution mass spectra; IC50, half-maximal inhibitory concentrations; Inhibitor; K. pneumoniae, Klebsiella pneumoniae; LQTS, long QT syndrome; MBLs, metallo-ß-lactamases class B; MEM, meropenem; MHA, Mueller-Hinton Agar; MHB, Mueller-Hinton Broth; MIC, minimum inhibitory concentration; NDM-1, New Delhi metallo-ß-lactamase-1; New Delhi metallo-ß-lactamase-1; PBS, phosphate-buffered saline; PK, pharmacokinetic; RBCs, red blood cells; SAR, structureactivity relationship; THF, tetrahydrofuran; TLC, thin layer chromatography; TMS, tetramethylsilane; Thiosemicarbazone derivatives; UPLC, ultra-performance liquid chromatography; conc. HCl, concentrated hydrochloric acid; r.t., room temperature
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Acta Pharm Sin B
Año:
2021
Tipo del documento:
Article
Pais de publicación:
Países Bajos